RS54904B1 - Antibakterijske farmaceutske kompozicije - Google Patents

Antibakterijske farmaceutske kompozicije

Info

Publication number
RS54904B1
RS54904B1 RS20160458A RSP20160458A RS54904B1 RS 54904 B1 RS54904 B1 RS 54904B1 RS 20160458 A RS20160458 A RS 20160458A RS P20160458 A RSP20160458 A RS P20160458A RS 54904 B1 RS54904 B1 RS 54904B1
Authority
RS
Serbia
Prior art keywords
pharmaceutical compositions
antibacterial pharmaceutical
pharmaceutically acceptable
antibacterial
bibenzo
Prior art date
Application number
RS20160458A
Other languages
English (en)
Serbian (sr)
Inventor
Francis Xavier Wilson
Peter David Johnson
Richard Vickers
Richard Storer
Graham Michael Wynne
Alan Geoffrey Roach
Moor Olivier De
Colin Richard Dorgan
Paul James Davis
Original Assignee
Summit Therapeutics Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Therapeutics Plc filed Critical Summit Therapeutics Plc
Publication of RS54904B1 publication Critical patent/RS54904B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
RS20160458A 2008-12-02 2009-12-01 Antibakterijske farmaceutske kompozicije RS54904B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0821913.1A GB0821913D0 (en) 2008-12-02 2008-12-02 Antibacterial compounds
EP14197877.5A EP2907813B1 (fr) 2008-12-02 2009-12-01 Compositions pharmaceutiques antibactérielles

Publications (1)

Publication Number Publication Date
RS54904B1 true RS54904B1 (sr) 2016-10-31

Family

ID=40262471

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20160458A RS54904B1 (sr) 2008-12-02 2009-12-01 Antibakterijske farmaceutske kompozicije

Country Status (28)

Country Link
US (3) US8975416B2 (fr)
EP (3) EP3095783A1 (fr)
JP (3) JP5665756B2 (fr)
KR (1) KR101643435B1 (fr)
CN (1) CN102227411B (fr)
AU (1) AU2009323854B2 (fr)
BR (2) BRPI0922220B8 (fr)
CA (1) CA2744962C (fr)
CY (2) CY1116383T1 (fr)
DK (2) DK2907813T3 (fr)
ES (2) ES2575908T3 (fr)
GB (1) GB0821913D0 (fr)
HK (2) HK1162169A1 (fr)
HR (2) HRP20150518T1 (fr)
HU (1) HUE029151T2 (fr)
IL (1) IL213325A (fr)
LT (1) LT2907813T (fr)
MX (1) MX2011005837A (fr)
NZ (1) NZ593111A (fr)
PL (2) PL2907813T3 (fr)
PT (2) PT2907813T (fr)
RS (1) RS54904B1 (fr)
RU (1) RU2525915C2 (fr)
SG (1) SG171939A1 (fr)
SI (2) SI2373631T1 (fr)
SM (2) SMT201500117B (fr)
WO (1) WO2010063996A2 (fr)
ZA (1) ZA201103751B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
DK2575968T3 (en) * 2010-06-01 2016-05-30 Summit Therapeutics Plc COMPOUNDS FOR THE TREATMENT OF Clostridium difficile-associated disease
GB2480814A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
GB2480813A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
GB2480816A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of Clostridium difficile associated diseases
WO2011151619A1 (fr) * 2010-06-01 2011-12-08 Summit Corporation Plc Composés destinés au traitement d'une maladie associée à clostridium difficile
WO2011151620A1 (fr) * 2010-06-01 2011-12-08 Summit Corporation Plc Composés pour le traitement d'une maladie associée à clostridium difficile
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102617655B1 (ko) 2012-11-23 2023-12-27 세레스 테라퓨틱스, 인코포레이티드 상승작용적 박테리아 조성물, 그리고 이의 제조 방법 및 용도
KR20230110367A (ko) 2013-02-04 2023-07-21 세레스 테라퓨틱스, 인코포레이티드 조성물 및 방법
EP2951283A4 (fr) 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions et procédés
EP2967077A4 (fr) 2013-03-15 2016-09-14 Seres Therapeutics Inc Compositions microbiennes et procédés associés basés sur un réseau
US10258655B2 (en) 2013-11-25 2019-04-16 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
WO2015095241A2 (fr) 2013-12-16 2015-06-25 Seres Health, Inc. Compositions bactériennes et leurs méthodes d'utilisation pour traiter des troubles du système immunitaire
JP6526956B2 (ja) * 2013-12-19 2019-06-05 花王株式会社 固形状組成物
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
KR102680943B1 (ko) 2017-08-14 2024-07-03 세레스 테라퓨틱스, 인코포레이티드 담즙정체성 질환 치료를 위한 조성물 및 방법
WO2019068383A1 (fr) * 2017-10-05 2019-04-11 Sandoz Ag Procédé de préparation de ridinilazole à l'aide de sels d'addition d'acide
KR20220024617A (ko) * 2019-07-17 2022-03-03 서밋 (옥스포드) 리미티드 리디닐라졸 및 이의 결정 형태의 제조방법
TW202128675A (zh) 2019-12-06 2021-08-01 美商維泰克斯製藥公司 作為鈉通道調節劑之經取代四氫呋喃
US20210324009A1 (en) * 2020-04-17 2021-10-21 The University Of Hong Kong Anti-bacterial calcium-dependent antibiotic (cda) analogs and methods of treating bacterial infections
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
GB202100470D0 (en) * 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
EP4346799A1 (fr) * 2021-05-24 2024-04-10 Aimmax Therapeutics, Inc. Combinaisons de pristinamycine ia et de flopristine dans le traitement ou la prévention d'infections bactériennes
PE20241335A1 (es) 2021-06-04 2024-07-03 Vertex Pharma N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
KR20240035395A (ko) 2021-06-14 2024-03-15 스코르피온 테라퓨틱스, 인코퍼레이티드 암 치료에 사용할 수 있는 요소 유도체
WO2024112631A1 (fr) * 2022-11-22 2024-05-30 Aimmax Therapeutics, Inc. Streptogramine à monothérapie pour le traitement ou la prévention d'infections bactériennes
EP4418810A1 (fr) 2023-02-15 2024-08-21 Siemens Aktiengesellschaft Procédé de surveillance assistée par ordinateur d'une installation industrielle au moyen d'un réseau radio

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3661849A (en) * 1965-10-06 1972-05-09 Ashland Oil Inc Heterocyclic polyimides prepared from heterocyclic diamines
US3503929A (en) 1965-10-21 1970-03-31 Minnesota Mining & Mfg Polyimidazoquinazolines and polyamidobenzimidazoles
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US4087409A (en) 1966-11-07 1978-05-02 Monsanto Company Ordered heterocyclic copolymers
JPS50140445A (fr) 1974-04-30 1975-11-11
JPS50154250A (fr) * 1974-05-31 1975-12-12
JPH03500661A (ja) 1988-06-09 1991-02-14 ザ・ダウ・ケミカル・カンパニー ベンゾキサゾール，ベンゾチアゾールまたはベンズイミダゾールの少なくとも１つの結合によって架橋したビスシクロブタレンのモノマー，オリゴマー及びポリマー
US5089592A (en) 1988-06-09 1992-02-18 The Dow Chemical Company Biscyclobutarene monomer comprising two cyclobutarene moieties bridged by a divalent radical comprising at least one benzothiazole or benzimidazole linkage
GB9108279D0 (en) * 1991-04-18 1991-06-05 Ucb Sa A method of preparing 1h-benzimidazoles
US5317078A (en) 1991-10-30 1994-05-31 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Polybenzimidazole via aromatic nucleophilic displacement
US5824698A (en) 1994-11-17 1998-10-20 Hoffman-La Roche Inc. Antibacterial dibenzimidazole derivatives
CN1164227A (zh) * 1994-11-17 1997-11-05 弗·哈夫曼-拉罗切有限公司 联苯并咪唑衍生物
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
JPH11158158A (ja) 1997-12-03 1999-06-15 Snow Brand Milk Prod Co Ltd 新規ベンゾイミダゾール誘導体
JPH11158156A (ja) 1997-12-03 1999-06-15 Earth Chem Corp Ltd 新規な１−（４−アルキルオキシフェニル）イミダゾール化合物
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
GB9908828D0 (en) 1999-04-16 1999-06-16 Univ Reading The Compounds
MXPA03004655A (es) 2000-11-27 2003-09-04 Ciba Sc Holding Ag Derivados 5-aril y 5-heteroaril-2-(2-hidroxifenil)-2h-benzotriazol substituidos como absorbentes de uv.
ES2331250T3 (es) 2000-12-15 2009-12-28 Vertex Pharmaceuticals Incorporated Inhibidores de la girasa bacteriana y usos de los mismos.
FR2819180B1 (fr) 2001-01-11 2003-02-21 Oreal Composition photoprotectrices a base de polymeres amphiphiles d'au moins un monomere a insaturation ethylique a groupement sulfonique et comportant une partie hydrophobe
WO2002060374A2 (fr) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Derives de benz-1,3-azole et leurs utilisations en tant qu'inhibiteurs de l'heparanase
AU2002367953C1 (en) 2001-05-04 2009-02-19 Paratek Pharmaceuticals, Inc Transcription factor modulating compounds and methods of use thereof
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2002334217B2 (en) 2001-10-26 2008-07-03 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
PL374191A1 (en) 2002-06-13 2005-10-03 Vertex Pharmaceuticals Incorporated 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
US20050260126A1 (en) * 2002-08-30 2005-11-24 Yukitsuka Kudo Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
CA2504448C (fr) 2002-11-01 2012-06-19 Paratek Pharmaceuticals, Inc. Composes modulant le facteur de transcription et methodes d'utilisation de ces derniers
AU2005324492B2 (en) 2004-04-23 2012-06-07 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
KR100629060B1 (ko) 2004-08-11 2006-09-26 주식회사 엘지화학 새로운 벤즈이미다졸계 화합물
CA2586375A1 (fr) 2004-11-04 2006-05-18 Juan-Miguel Jimenez Pyrazolo[1,5-a]pyrimidines utiles en tant qu'inhibiteurs de proteines kinases
CA2594665A1 (fr) 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles utiles dans le traitement de l'inflammation
CA2617123C (fr) 2005-08-12 2015-05-26 United States Government As Represented By The Secretary Of The United States Army And The U.S. Army Medical Research & Materiel Command Composes antibacteriens a large spectre
JP2009514894A (ja) 2005-11-07 2009-04-09 バーテックス ファーマシューティカルズ インコーポレイテッド ジャイレース阻害剤としてのベンズイミダゾール誘導体
KR100744827B1 (ko) 2006-04-05 2007-08-01 한국화학연구원 트리플루오로비닐옥시기를 포함하는 불소계 벤즈이미다졸 단량체 및 이의 제조방법
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
CN103641829A (zh) 2006-08-30 2014-03-19 塞尔佐姆有限公司 作为激酶抑制剂的三唑衍生物
PE20080888A1 (es) * 2006-10-18 2008-08-26 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE LA ACIL-TRANSFERASA DE ACIL-CoA-DIACIL-GLICEROL 1 (DGAT1)
WO2008073451A2 (fr) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Composés modulateurs de la sirtuine
CA2672815A1 (fr) 2006-12-15 2008-06-26 Pfizer Products Inc. Derives du benzamidazole
JP5502076B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規化合物
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101022649B1 (ko) 2008-08-07 2011-03-22 삼성모바일디스플레이주식회사 헤테로고리 화합물 및 이를 이용한 유기 전계 발광 장치
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2010099527A1 (fr) 2009-02-27 2010-09-02 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
KR101219487B1 (ko) 2009-03-03 2013-01-15 덕산하이메탈(주) 비스벤조이미다졸 화합물 및 이를 이용한 유기전기소자, 그단말
EP2414369B1 (fr) 2009-04-02 2015-08-12 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Derivé de Imidazo[2,1-b][1,3,4]thiadiazole
CN102459265A (zh) 2009-05-27 2012-05-16 雅培制药有限公司 激酶活性的嘧啶抑制剂
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
CA2765534C (fr) 2009-06-15 2018-09-18 Rigel Pharmaceuticals, Inc. Inhibiteurs a petite molecule de la tyrosine kinase de la rate (syk)
ES2749504T3 (es) 2009-10-13 2020-03-20 Ligand Pharm Inc Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
DK2575968T3 (en) 2010-06-01 2016-05-30 Summit Therapeutics Plc COMPOUNDS FOR THE TREATMENT OF Clostridium difficile-associated disease

Also Published As

Publication number Publication date
ES2575908T3 (es) 2016-07-04
CN102227411A (zh) 2011-10-26
PL2907813T3 (pl) 2016-09-30
EP2373631B1 (fr) 2015-02-25
BR122020013025B1 (pt) 2021-05-18
CN102227411B (zh) 2015-10-14
HRP20160597T1 (hr) 2016-09-23
DK2907813T3 (en) 2016-07-25
KR20110093925A (ko) 2011-08-18
HRP20150518T1 (hr) 2015-07-17
SMT201600259B (it) 2016-08-31
BRPI0922220B8 (pt) 2021-05-25
US8975416B2 (en) 2015-03-10
ZA201103751B (en) 2014-10-29
HUE029151T2 (hu) 2017-02-28
EP3095783A1 (fr) 2016-11-23
GB0821913D0 (en) 2009-01-07
US20120020950A1 (en) 2012-01-26
PT2373631E (pt) 2015-06-09
JP2015078220A (ja) 2015-04-23
JP2017048217A (ja) 2017-03-09
PL2373631T3 (pl) 2015-10-30
CY1117934T1 (el) 2017-05-17
BRPI0922220B1 (pt) 2021-03-09
SMT201500117B (it) 2015-07-09
RU2011127165A (ru) 2013-01-10
JP5665756B2 (ja) 2015-02-04
LT2907813T (lt) 2016-10-10
SI2907813T1 (sl) 2016-09-30
IL213325A (en) 2016-02-29
IL213325A0 (en) 2011-07-31
PT2907813T (pt) 2016-08-05
DK2373631T3 (en) 2015-05-26
MX2011005837A (es) 2011-11-18
JP2012510458A (ja) 2012-05-10
US20160184283A1 (en) 2016-06-30
AU2009323854A1 (en) 2010-06-10
WO2010063996A2 (fr) 2010-06-10
BRPI0922220A2 (pt) 2015-12-29
WO2010063996A3 (fr) 2010-12-29
EP2373631A2 (fr) 2011-10-12
CA2744962A1 (fr) 2010-06-10
EP2907813A1 (fr) 2015-08-19
US20150150861A1 (en) 2015-06-04
NZ593111A (en) 2013-05-31
BRPI0922220A8 (pt) 2018-04-03
KR101643435B1 (ko) 2016-07-27
HK1162169A1 (en) 2012-08-24
ES2537059T3 (es) 2015-06-02
SI2373631T1 (sl) 2015-08-31
CY1116383T1 (el) 2017-02-08
EP2907813B1 (fr) 2016-04-27
HK1208668A1 (zh) 2016-03-11
US9314456B2 (en) 2016-04-19
SG171939A1 (en) 2011-07-28
AU2009323854B2 (en) 2014-06-26
AU2009323854A2 (en) 2011-06-30
CA2744962C (fr) 2017-06-06
RU2525915C2 (ru) 2014-08-20
US9763925B2 (en) 2017-09-19

Similar Documents

Publication Publication Date Title
RS54904B1 (sr) Antibakterijske farmaceutske kompozicije
UA92637C2 (en) Pyridine[3,4-b]pyrazinones
UA94901C2 (ru) Антибактериальные производные пиперидина
IL192948A0 (en) Novel pyridine derivatives
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
ATE433980T1 (de) Gyraseinhibitoren und deren verwendungen
WO2010057118A3 (fr) Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
WO2007143434A3 (fr) Activateurs de glucokinase
IL192298A (en) Heterocyclic Compounds, Their Acceptable Salts, Pharmaceuticals Containing and Using Them
CL2009000228A1 (es) Compuestos derivados de 7,8-dihidropirido[4,3-d]pirimidin con un sustituyente oximico, inhibidores de hsp90; y composicion farmaceutica que comprene a dichos compuestos.
MX2010009163A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211.
WO2006092599A3 (fr) Composes chimiques
WO2007106537A3 (fr) Aminoquinolones utilisées comme inhibiteurs de la gsk-3
WO2008020227A3 (fr) Composés chimiques
WO2008020229A3 (fr) Composés chimiques
UA101313C2 (uk) Щотижневе введення інгібіторів дипептидилпептидази
UA90742C2 (en) Pyrazolone derivatives
WO2007034279A3 (fr) Antagonistes de c3a et leurs compositions pharmaceutiques
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
WO2006087544A8 (fr) Composes chimiques
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
MX2010013310A (es) Derivados de heterociclil urea para el tratamiento de infecciones bacterianas.
WO2009035634A3 (fr) Cyanoaminoquinolones et tétrazoloaminoquinolones en tant qu'inhibiteurs de gsk-3
WO2011005052A8 (fr) Nouveaux dérivés imidazole-4-carboxamide contenant de l'arylpipérazine et composition pharmaceutique contenant ces dérivés